pamidronate has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 2 studies
Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kuroda, J | 1 |
| Kimura, S | 1 |
| Segawa, H | 1 |
| Kobayashi, Y | 1 |
| Yoshikawa, T | 1 |
| Urasaki, Y | 1 |
| Ueda, T | 1 |
| Enjo, F | 1 |
| Tokuda, H | 1 |
| Ottmann, OG | 1 |
| Maekawa, T | 1 |
| Sawyer, N | 1 |
| Newstead, C | 1 |
| Drummond, A | 1 |
| Newland, A | 1 |
| Cunningham, J | 1 |
2 other studies available for pamidronate and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate.
Topics: Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; | 2003 |
One-shot high-dose pamidronate disodium (APD): effective, simple treatment for hypercalcaemia in haematological malignancy.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Diphosphonates; Drug Administration Schedule; | 1989 |